

References:

- A. FAO/WHO. Guidelines for the evaluation of probiotics in food. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report, 2002.
- B. Clarke TC, Black LI, Stussman BG, et al. Trends in the use of complementary health approaches among adults: United States, 2002-2012. US Department of Health and Human Services. *Nat Health Stat Reports* 10 Feb 2015:79.
- C. Barchiesi F, Arzeni D, Compagnucci P, et al. In vitro activity of five antifungal agents against clinical isolates of *Saccharomyces cerevisiae*. *Med Mycol*.1998;36:437-440.
- D. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in *Saccharomyces boulardii* fungemia. *Eur J Clin Microbiol Infect Dis*. 2000;19:16-20.
- E. Enache-Angoulvant A, Hennequin C. Invasive *Saccharomyces* infection: a comprehensive review, *Clin Infect Dis*. Dec 2005;41:1559-1568.
- F. Chitasombat MN, Kofteridis DP, Jiang Y, et al. Rare opportunistic (non-*Candida*, non-*Cryptococcus*) yeast bloodstream infections in patients with cancer. *J Infect*. Jan 2012;64(1). DOI: 10.1016/j.jinf.2011.11.002.
- G. Costa RL, Moreira J, Lorenzo A, et al. Infectious complications following probiotic ingestion: a potentially underestimated problem? A systematic review of reports and case series. *Comp and Alt Medicine*. 2018;18(329):1-8. DOI: 10.1186/s12906-018-2394-3.
- H. McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: society of critical care medicine (SCCM) and American society for parenteral and enteral nutrition (ASPEN). *J Parent Ent Nutr*. Feb 2016;40(2):159-211. DOI: 10.1177/0148607115621863.
- I. Barraud D, Blard C, Hein F, et al. Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. *Intensive Care Med*. 2010;36:1540-1547. DOI: 10.1007/s00134-010-1927-0.
- J. Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents *Clostridium difficile* infection: A systematic review with meta-regression analysis. *Gastroenterology*. 2017;152:1889-1900. DOI: 10.1053/j.gastro.2017.02.003.
- K. Goldenburg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of *Clostridium difficile* associated diarrhea in adults and children. *Cochrane Database Syst Rev*. Dec 2017. Issue 12. Art. No.: CD006095. DOI: 10.1002/14651858.CD006095.pub4
- L. McDonald LC, Gerdling DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the infectious disease society of America (IDSA) and society for healthcare epidemiology of America (SHEA). *Clin Infect Dis*. 2018;66(7):e1-48. DOI: 10.1093/cid/cix1085.
- M. Johnston BC, Ma SSY, Godenberg JZ, et al. Probiotics for the prevention of *Clostridium difficile* associated diarrhea. A systemic review and meta-analysis. *Ann Intern Med*. Dec 2012;157(12):878-888. DOI: 10.7326/0003-4819-157-12-201212180-00563
- N. Ford AC, Harris LA, Lacy BE, et al. Systematic review with meta-analysis the efficacy of prebiotics, probiotics, synbiotics, and antibiotics in irritable bowel syndrome. *Aliment Pharmacol Ther*. Sept 2018;48:1044-1060. DOI: 10.1111/apt.15001.
- O. Cai J, Zhao C, Du Y, et al. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: systematic review with network meta-analysis. *Unit Euro Gastroent Jour*. Sept 2017;6(2):169-180. DOI: 10.1177/2050640617736987
- P. Ehrhardt S, Gua N, Hinz R, et al. *Saccharomyces boulardii* to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. *Open Forum Infect Dis*. 2016 Jan 29;3(1):ofw011. DOI: 10.1093/ofid/ofw011.
- Q. Pfaller MA, Diekema DJ, Merz WG. *Clinical Mycology*. Published 2009. Edition 2. Chapter 10. PP251-270.
- R. Tiballi RN, Spiegel JE, Zarins LT, et al. *Saccharomyces cerevisiae* infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. *Diagn Microbiol Infect Dis*. Oct 1995;23:135-140.
- S. Bennet WE. Quantitative risk-benefit analysis of probiotic use for irritable bowel syndrome and inflammatory bowel disease. *Drug Safety*. 2015;1-11. DOI: 10.1007/s40264-015-0349-x.
- T. Walgreens vitamins and supplements – shop probiotics. Walgreens Co., Deerfield, IL. Accessed: 12 Jan 2019. <https://www.walgreens.com/store/c/probiotics/ID=360555-tier2general>